AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12915334 — intervention group
Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA) supplementation, with a daily dose of up to 2.6 grams of fish oil (equivalent to about 1.6 grams of EPA)
Number of subjects: 12
Study 12915334 — intervention group
Group type: COMPARATOR
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 12
Study 12915334 — intervention group
Group type: COMPARATOR
Intervention: Reduction of dietary arachidonic acid
Number of subjects: 12
Study 11910618 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype patch
Number of subjects: 20
Study 11910618 — intervention group
Group type: EXPERIMENTAL
Intervention: Industrial counterpart patch
Number of subjects: 20
Study 11910618 — intervention group
Group type: EXPERIMENTAL
Intervention: Reservoir patch (Estraderm TTS 50)
Number of subjects: 20
Study 11910618 — intervention group
Group type: COMPARATOR
Intervention: Reference matrix patch (System 50)
Number of subjects: 20
Study 9162737 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34 positive (CD34+) spindle cells in hypertrophic scars and keloids
Number of subjects: 0
Study 9162737 — intervention group
Group type: COMPARATOR
Intervention: Non-inflammatory scars or non-inflammatory central portion of keloids
Number of subjects: 0
Study 9162737 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34-proline‐4‐hydroxylase+ cells during inflammation subsiding
Number of subjects: 0
Study 9162737 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34 expression in relation to type I collagen synthesis
Number of subjects: 0
Study 7835364 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated anticardiolipin antibody (ACLA) titres (IgM and IgG)
Number of subjects: 57
Study 7835364 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated anticardiolipin antibody (ACLA) titres (IgG)
Number of subjects: 57
Study 7835364 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of anti-heart muscle antibodies (AHA) > or = 2+
Number of subjects: 57
Study 3288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50mg
Number of subjects: 3
Study 3288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20mg
Number of subjects: 3
Study 3288468 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Atenolol and Nifedipine
Number of subjects: 3
Study 3288468 — intervention group
Group type: COMPARATOR
Intervention: Control (individual components)
Number of subjects: 3
Study 29580446 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicago Urban Resiliency Building (CURB) intervention
Number of subjects: 28
Study 29580446 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic staff exit interviews
Number of subjects: 28
Study 29580446 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care providers and clinic staff surveys
Number of subjects: 28
Study 26276915 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after SCA
Number of subjects: 91
Study 26276915 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of myocardial infarction without SCA
Number of subjects: 91
Study 26276915 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 91
Study 23690410 — intervention group
Group type: EXPERIMENTAL
Intervention: CanChange intervention (11 theory‐based telephone‐delivered health coaching sessions over 6 months)
Number of subjects: 410
Study 23690410 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 410
Study 19458956 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia (group A)
Number of subjects: 80
Study 19458956 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (group B)
Number of subjects: 80
Study 18983380 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline douching (3 times per day for 6 weeks)
Number of subjects: 23
Study 16911315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of half-isotonic saline (1 mL/kg/h) for 12 h before surgery (hydration group)
Number of subjects: 45
Study 16911315 — intervention group
Group type: COMPARATOR
Intervention: Fluid restriction (control group)
Number of subjects: 45
Study 16911315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of half-isotonic saline (hydration group)
Number of subjects: 45
Study 12796167 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug treatment (TDG) - albuterol, ipratropium bromide, and flunisolide
Number of subjects: 172
Study 12796167 — intervention group
Group type: COMPARATOR
Intervention: A/IB (albuterol and ipratropium bromide)
Number of subjects: 172
Study 12796167 — intervention group
Group type: COMPARATOR
Intervention: A/F (albuterol and flunisolide)
Number of subjects: 172
Study 10968813 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg hypericum extract ZE 117 twice daily for 6 weeks
Number of subjects: 324
Study 10968813 — intervention group
Group type: COMPARATOR
Intervention: 75 mg imipramine twice daily for 6 weeks
Number of subjects: 324
Study 8917818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dots replotted in random positions in each new frame
Number of subjects: 0
Study 8917818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dots with a set displacement but following a random walk
Number of subjects: 0
Study 8917818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dots moving in random directions which remain constant for a given dot
Number of subjects: 0
Study 8917818 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal dots may either remain the same or be re-selected afresh on each frame
Number of subjects: 0
Study 1767901 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal cisapride 30 mg and intramuscular morphine 10 mg
Number of subjects: 40
Study 1767901 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal cisapride 60 mg and intramuscular morphine 10 mg
Number of subjects: 40
Study 1767901 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories and intramuscular morphine 10 mg
Number of subjects: 40
Study 1767901 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories only
Number of subjects: 40
Study 6805590 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment
Number of subjects: 37
Study 6805590 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 37
Study 6805590 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 37
Study 6805590 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxation
Number of subjects: 37
Study 6805590 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback
Number of subjects: 37
Study 6805590 — intervention group
Group type: COMPARATOR
Intervention: Salt restriction
Number of subjects: 37
Study 31408478 — intervention group
Group type: EXPERIMENTAL
Intervention: Seroprevalence of VZV
Number of subjects: 1184
Study 31408478 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported history of VZV infection
Number of subjects: 1184
Study 29066145 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen (4 doses of 1 g over 15 minutes every 6 hours for 24 hours)
Number of subjects: 0
Study 29066145 — intervention group
Group type: COMPARATOR
Intervention: IV placebo (saline placebo, equal volume to acetaminophen)
Number of subjects: 0
Study 26875489 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg menaquinone-7 daily for 12 weeks (Study 2)
Number of subjects: 180
Study 26875489 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 μg menaquinone-7 daily for 4 weeks (Study 1)
Number of subjects: 180
Study 26875489 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg menaquinone-7 daily for 4 weeks (Study 1)
Number of subjects: 180
Study 26875489 — intervention group
Group type: COMPARATOR
Intervention: 0 μg menaquinone-7 daily (Study 1)
Number of subjects: 180
Study 26875489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 2)
Number of subjects: 180
Study 24185214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie Optimism: Positive Thinking Skills Program (AOP‐PTS)
Number of subjects: 910
Study 24185214 — intervention group
Group type: COMPARATOR
Intervention: Regular Health Education curriculum (Control)
Number of subjects: 910
Study 24185214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Intervention and Control)
Number of subjects: 910
Study 21321617 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-glass powder and bio-glass paste
Number of subjects: 60
Study 21321617 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-glass powder
Number of subjects: 60
Study 21321617 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-glass paste
Number of subjects: 60
Study 21321617 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 60
Study 21321617 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-glass powder or paste
Number of subjects: 60
Study 19519874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (DL) and placebo gel
Number of subjects: 45
Study 19519874 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo laser and NK10% gel
Number of subjects: 45
Study 19519874 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser and placebo gel
Number of subjects: 45
Study 17198098 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (40 microg, 2.5 microg/mL)
Number of subjects: 120
Study 17198098 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (80 microg, 5 microg/mL)
Number of subjects: 120
Study 17198098 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (160 microg, 10 microg/mL)
Number of subjects: 120
Study 17198098 — intervention group
Group type: COMPARATOR
Intervention: Control group (without epinephrine)
Number of subjects: 120
Study 17198098 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine-containing lidocaine solution (all groups)
Number of subjects: 120
Study 15072808 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (up to 300 mg per day) plus counselling and support
Number of subjects: 493
Study 15072808 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus counselling and support
Number of subjects: 493
Study 11240972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone and terfenadine
Number of subjects: 0
Study 11240972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone and loratadine
Number of subjects: 0
Study 11240972 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine alone
Number of subjects: 0
Study 11240972 — intervention group
Group type: COMPARATOR
Intervention: Loratadine alone
Number of subjects: 0
Study 11240972 — intervention group
Group type: COMPARATOR
Intervention: Nefazodone alone
Number of subjects: 0
Study 11240972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone with terfenadine
Number of subjects: 0
Study 11240972 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone with loratadine
Number of subjects: 0
Study 9505799 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (25% energy from fat)
Number of subjects: 20
Study 9505799 — intervention group
Group type: COMPARATOR
Intervention: Medium-fat diet (41% energy from fat)
Number of subjects: 20
Study 7663138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg p.o.)
Number of subjects: 46
Study 7663138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7663138 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (20 mg p.o.)
Number of subjects: 46
Study 2660562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times per day)
Number of subjects: 60
Study 2660562 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice per day)
Number of subjects: 60
Study 2660562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g twice per day)
Number of subjects: 60
Study 2660562 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg before bed)
Number of subjects: 60
Study 2660562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60
Study 2660562 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 60
Study 31769891 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and telephone follow-up intervention based on the Roy Adaptation Model
Number of subjects: 66
Study 31769891 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus telephone follow-up intervention
Number of subjects: 66
Study 31769891 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 66
Study 30824917 — intervention group
Group type: EXPERIMENTAL
Intervention: VHost-Classifier
Number of subjects: 1000
Study 28146403 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 111
Study 28146403 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 111
Study 25724409 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (150 min per week, for 12 weeks) and diet counseling
Number of subjects: 23
Study 22745189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (400 mg, selective D2 antagonist)
Number of subjects: 23
Study 22745189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 23
Study 21224867 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilberries (BB)
Number of subjects: 80
Study 21224867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn (SB)
Number of subjects: 80
Study 21224867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn phenolic extract (SBe)
Number of subjects: 80
Study 21224867 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBo)
Number of subjects: 80
Study 19104406 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/DAC
Number of subjects: 602
Study 19104406 — intervention group
Group type: COMPARATOR
Intervention: TAC/MMF
Number of subjects: 602
Study 16822120 — intervention group
Group type: EXPERIMENTAL
Intervention: Homework compliance during cognitive-behavioral therapy (CBT)
Number of subjects: 123
Study 12643517 — intervention group
Group type: EXPERIMENTAL
Intervention: Coasted group (n = 157)
Number of subjects: 365
Study 12643517 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 208)
Number of subjects: 365
Study 10866898 — intervention group
Group type: EXPERIMENTAL
Intervention: REM/PRO (75 microg. kg(‐1). min(‐1))
Number of subjects: 120
Study 10866898 — intervention group
Group type: EXPERIMENTAL
Intervention: REM/DES (0.5 minimum alveolar anesthetic concentration)
Number of subjects: 120
Study 10866898 — intervention group
Group type: EXPERIMENTAL
Intervention: REM/SEVO (0.5 minimum alveolar anesthetic concentration)
Number of subjects: 120
Study 10866898 — intervention group
Group type: COMPARATOR
Intervention: Thiopental/alfentanil/isoflurane/N(2)O (control group)
Number of subjects: 120
Study 9069159 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular BMD in women aged 55-69 years
Number of subjects: 122
Study 9069159 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular texture index in women aged 70-79 years
Number of subjects: 122
Study 9069159 — intervention group
Group type: EXPERIMENTAL
Intervention: I-texture in women aged 55-59 years
Number of subjects: 122
Study 9069159 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle area in women aged 60-69 years
Number of subjects: 122
Study 9069159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical BMD and muscle area in women aged 70-79 years
Number of subjects: 122
Study 8472110 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) as the insufflation agent
Number of subjects: 142
Study 8472110 — intervention group
Group type: COMPARATOR
Intervention: Air as the insufflation agent
Number of subjects: 142
Study 2581322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0
Study 2581322 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 0
Study 31501905 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT)
Number of subjects: 20
Study 29743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissonance-based intervention consisting of four group sessions three months post-surgery
Number of subjects: 259
Study 29743040 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up care (Control group)
Number of subjects: 259
Study 27191255 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary canine retraction using mini-implants as anchorage for approximately 4 months with 100g of force via coil springs.
Number of subjects: 24
Study 27191255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no orthodontic treatment).
Number of subjects: 24
Study 25029424 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 17
Study 25029424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22583843 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency stimulation (HFS) of the left atrium, n = 15
Number of subjects: 30
Study 22583843 — intervention group
Group type: COMPARATOR
Intervention: No high-frequency stimulation (Control), n = 15
Number of subjects: 30
Study 20574929 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100
Study 20574929 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 100
Study 18030072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg)
Number of subjects: 20
Study 18030072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15651944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular naloxone (2 mg)
Number of subjects: 155
Study 15651944 — intervention group
Group type: COMPARATOR
Intervention: Intranasal naloxone (2 mg)
Number of subjects: 155
Study 12186247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal music
Number of subjects: 47
Study 12186247 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 47
Study 12186247 — intervention group
Group type: COMPARATOR
Intervention: Natural sound (murmurings of a stream)
Number of subjects: 47
Study 12186247 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 47
Study 10570736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical support of minute ventilation for chronic but stable diseases (e.g., old polio, quadriplegia, kyphoscoliosis)
Number of subjects: 0
Study 10570736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical support of minute ventilation for chronic and progressive diseases (e.g., muscular dystrophy, amyotrophic lateral sclerosis)
Number of subjects: 0
Study 7598463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment of IDDM patients
Number of subjects: 0
Study 7598463 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved glycemic control in NIDDM patients
Number of subjects: 0
Study 7598463 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment recommendations
Number of subjects: 0
Study 7598463 — intervention group
Group type: EXPERIMENTAL
Intervention: Any improvement in glycemic control
Number of subjects: 0
Study 7598463 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of insulin in NIDDM patients
Number of subjects: 0
Study 2357093 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 64
Study 2357093 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 64
Study 786832 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-Demoplas
Number of subjects: 0
Study 786832 — intervention group
Group type: COMPARATOR
Intervention: Control (antiphologistic containing high dosage of vitamin B complex and Metamizol)
Number of subjects: 0
Study 31928505 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat (WC)
Number of subjects: 1400
Study 31928505 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist team (ST)
Number of subjects: 1400
Study 31928505 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WeChat and Specialist team (WC-ST)
Number of subjects: 1400
Study 31928505 — intervention group
Group type: COMPARATOR
Intervention: Service as usual (SAU)
Number of subjects: 1400
Study 31695350 — intervention group
Group type: EXPERIMENTAL
Intervention: EX+NEPA
Number of subjects: 40
Study 31695350 — intervention group
Group type: COMPARATOR
Intervention: EX
Number of subjects: 40
Study 27387522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV) therapy
Number of subjects: 31
Study 27387522 — intervention group
Group type: COMPARATOR
Intervention: Conservative therapy (non-ASV)
Number of subjects: 31
Study 25289711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g L-carnitine
Number of subjects: 26
Study 25289711 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g L-carnitine
Number of subjects: 26
Study 25289711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23660990 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg droperidol
Number of subjects: 72
Study 23660990 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 72
Study 23660990 — intervention group
Group type: COMPARATOR
Intervention: Saline (1 ml)
Number of subjects: 72
Study 22164964 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium enteric coated tablets (test formulation)
Number of subjects: 0
Study 22164964 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium enteric coated tablets (reference formulation)
Number of subjects: 0
Study 19958553 — intervention group
Group type: EXPERIMENTAL
Intervention: Con‐Dis device
Number of subjects: 10
Study 19958553 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire-based assessment (RAI and RAVA)
Number of subjects: 10
Study 16942535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 68
Study 16942535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 15557875 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Number of subjects: 0
Study 11096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hormonal deprivation using luteinizing hormone-releasing hormone (LHRH) analogue alone (n = 11)
Number of subjects: 43
Study 11096234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hormonal deprivation associated with an antiandrogen (n = 32)
Number of subjects: 43